Abbvie

AbbVie Inc. (NYSE:ABBV) ‘s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas — immunology, oncology, neuroscience, and eye care — and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Abbvie Inc. (NYSE:ABBV) Net Revenues grew 1.6% YoY to $15.121 Billion in Q4 2022

/ / Health Care /

February 9, 2023 – Abbvie Inc. (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2022. reported Q4 adjusted earnings  of $3.60 per diluted share, Analysts polled by Capital IQ expected $3.58. Revenue for the quarter ended Dec. 31 was $15.12 billion, Analysts surveyed by Capital IQ expected $15.30 billion. For the full year of 2023, the company is expecting adjusted earnings of $10.70 to $11.10 per diluted share. Analysts polled by Capital IQ are expecting $11.68. AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results Reports Full-Year Diluted EPS of $6.63 on a GAAP Basis, an Increase of 2.8 Percent; Adjusted Diluted EPS of $13.77, an Increase of 16.4 Percent; Delivers Full-Year Net Revenues of $58.054 Billion, an Increase of 3.3 Percent on a Reported Basis and 5.1 Percent on an Operational Basis。 Reports Fourth-Quarter Diluted EPS of $1.38 on a GAAP Basis, a decrease […]

Abbvie Inc. (NYSE:ABBV) Net Revenues grew 1.6% YoY to $15.121 Billion in Q4 2022 Read Post »

Scroll to Top